Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer
Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.
- Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.
- Before joining Verge, Dr. Cadavid served as Chief Medical Officer of X4 Pharmaceuticals where he led the clinical development of mavorixafor and recently delivered positive phase 3 data.
- His work included the rapid advance of losmapimod from target identification to proof of concept in Facioscapulohumeral Muscular Dystrophy (FSHD).
- What stands out to me most, though, is his knack using disruptive innovation to enable disciplined execution, said Alice Zhang, CEO and co-founder of Verge Genomics.